PGGM Investments Boosts Holdings in Illumina, Inc. (NASDAQ:ILMN)

PGGM Investments grew its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 39.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 211,834 shares of the life sciences company's stock after acquiring an additional 60,384 shares during the quarter. PGGM Investments owned about 0.13% of Illumina worth $29,496,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of ILMN. Eukles Asset Management lifted its position in Illumina by 1.7% in the third quarter. Eukles Asset Management now owns 5,942 shares of the life sciences company's stock worth $816,000 after buying an additional 100 shares during the last quarter. Clear Creek Financial Management LLC increased its stake in Illumina by 6.3% in the fourth quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company's stock worth $236,000 after purchasing an additional 100 shares during the period. Lido Advisors LLC increased its stake in Illumina by 6.1% in the third quarter. Lido Advisors LLC now owns 1,859 shares of the life sciences company's stock worth $255,000 after purchasing an additional 107 shares during the period. Quent Capital LLC increased its stake in Illumina by 45.2% in the fourth quarter. Quent Capital LLC now owns 363 shares of the life sciences company's stock worth $51,000 after purchasing an additional 113 shares during the period. Finally, Independent Advisor Alliance increased its stake in Illumina by 8.6% in the third quarter. Independent Advisor Alliance now owns 1,595 shares of the life sciences company's stock worth $219,000 after purchasing an additional 126 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ILMN. Stephens reiterated an "overweight" rating and issued a $170.00 target price on shares of Illumina in a research note on Wednesday, April 10th. Royal Bank of Canada reiterated an "outperform" rating and issued a $253.00 target price on shares of Illumina in a research note on Tuesday, April 9th. TD Cowen lowered Illumina from an "outperform" rating to a "market perform" rating and set a $144.00 price target on the stock. in a research note on Thursday, January 4th. Barclays raised their price target on Illumina from $85.00 to $100.00 and gave the company an "underweight" rating in a research note on Wednesday, April 10th. Finally, OTR Global restated a "mixed" rating on shares of Illumina in a research note on Wednesday, March 20th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $167.70.

Insiders Place Their Bets

In other news, CEO Jacob Thaysen bought 7,330 shares of the firm's stock in a transaction that occurred on Thursday, February 22nd. The stock was purchased at an average price of $135.29 per share, with a total value of $991,675.70. Following the completion of the acquisition, the chief executive officer now directly owns 14,861 shares of the company's stock, valued at approximately $2,010,544.69. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.17% of the company's stock.

Illumina Stock Up 1.0 %

NASDAQ ILMN traded up $1.23 during trading on Friday, hitting $122.28. The company's stock had a trading volume of 829,331 shares, compared to its average volume of 1,470,247. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29. The company has a market cap of $19.47 billion, a PE ratio of -16.66 and a beta of 1.19. The business's 50 day simple moving average is $131.51 and its 200-day simple moving average is $127.31. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $213.91.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.13. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The company's quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the company earned $0.14 earnings per share. On average, equities analysts anticipate that Illumina, Inc. will post 0.91 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.